Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 4771 Download: 349 Web of Science: 9 Crossref: 11

Snapshot

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease

Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen

Clin Mol Hepatol. 2025;31(3):1100-1102. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1090

View: 931 Download: 103

Correspondence

GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e189-e191. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0120

View: 854 Download: 30 Crossref: 1

Review

Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer

Chenyang Li, Chujun Cai, Chendong Wang, Xiaoping Chen, Bixiang Zhang, Zhao Huang

Clin Mol Hepatol. 2025;31(2):350-381. Published online December 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0857

View: 3034 Download: 289 Web of Science: 2 Crossref: 3

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 2907 Download: 203 Web of Science: 2 Crossref: 3

Original Article

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Clin Mol Hepatol. 2024;30(4):845-862. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349

View: 6916 Download: 1,006 Web of Science: 8 Crossref: 8

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Clin Mol Hepatol. 2024;30(3):582-584. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555

View: 10247 Download: 106

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

View: 6944 Download: 180 Web of Science: 14 Crossref: 13

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0202

View: 8225 Download: 209 Web of Science: 30 Crossref: 29

Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Shiv Kumar Sarin, Shvetank Sharma

Clin Mol Hepatol. 2020;26(4):639-651. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0196

View: 10523 Download: 279 Web of Science: 12 Crossref: 13

Review

Fecal microbiota transplantation in alcohol related liver diseases

Saggere Muralikrishna Shasthry

Clin Mol Hepatol. 2020;26(3):294-301. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0057

View: 8897 Download: 246 Web of Science: 31 Crossref: 34

Microbiota, a key player in alcoholic liver disease

Anne-Marie Cassard, Dragos Ciocan

Clin Mol Hepatol. 2018;24(2):100-107. Published online December 22, 2017

DOI: https://doi.org/10.3350/cmh.2017.0067

View: 13987 Download: 548 Web of Science: 75 Crossref: 76

1 |

Viewed By 12379	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7576	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7009	MAFLD: How is it different from NAFLD?
Viewed By 5631	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5462	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search